Victory For Takeda Abbott In Prostate Drug Patent Suit

Law360, New York (December 14, 2005, 12:00 AM EST) -- A jury has upheld a patent for a prostate cancer treatment held by Takeda Abbott Pharmaceuticals, marking a victory for the company in its litigation against pharmaceutical companies QLT Inc. and Sanofi-Synthelabo.

QLT said it plans to appeal the jury verdict.

TAP, a joint venture between Takeda Chemical Industries and Abbot Laboratories, filed the suit in 2003, alleging that the Eligard prostate cancer treatment controlled by all three defendants infringes a TAP patent.

Eligard was developed by Atrix Laboratories, which was purchased by QLT in November...
To view the full article, register now.